All Press Releases
Pila Pharma AB announces certification of API
Malmö, Sweden, April 25, 2022 Download the press release as PDF here Pila Pharma AB (PILA) today announces that the study material (non-GMP API) to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety…
Pila Pharma bygger pipeline – ansöker om Orphan Drug Designation i USA
Malmö, 22 april, 2022 Läs pressmeddelandet som PDF här Pila Pharma AB meddelar att bolaget har ansökt om Orphan Drug Designation (särläkemedelsstatus) vid U.S. Food and Drug Administration, FDA, för utvecklingskandidaten XEN-D0501. Syftet är att ta fram en behandling av en sjukdom förknippad med smärta på grund av neurogen inflammation. Pila Pharmas utvecklingskandidat XEN-D0501 är under utveckling för behandling av…
Pila Pharma builds pipeline – applies for Orphan Drug Designation in the USA
Malmö, 22 April, 2022 Download the press release as PDF here Pila Pharma AB announces that the company has submitted a request for an Orphan Drug Designation to the U.S. Food and Drug Administration (FDA) for the company’s development candidate XEN-D0501. The aim is to develop a novel treatment of a rare disease associated with pain due to neurogenic inflammation. Pila Pharma's…